Honest Criticisms and Limitations of the REWIND Trial
A critical analysis of the REWIND cardiovascular outcomes trial for dulaglutide, covering enrollment biases, generalizability gaps, statistical nuances, and post-publication commentary.
Trials Rewind
4 source-based articles maintained by the HealthRX.com Editorial Team.
4articles
2topic areas covered
May 25, 2026latest review
Trials Rewind library
Showing 4 of 4 clinical reviews.
REWIND Trial: A Plain-English Overview of What It Established
A plain-English deep dive into the REWIND cardiovascular outcomes trial for dulaglutide (Trulicity) in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
REWIND Trial: Dulaglutide CV Outcomes, HR 0.88 Explained
REWIND trial results: dulaglutide cut three-point MACE by 12% (HR 0.88, 95% CI 0.79-0.99) over 5.4 years in 9,901 patients, per the 2019 Lancet publication.
What REWIND Actually Changes in Clinical Practice
A deep dive into the REWIND trial's 12% MACE reduction with dulaglutide and what it means for real-world prescribing in type 2 diabetes, including guideline updates, patient selection, and primary prevention implications.
